## **Zurzuvae Enrollment Form**



Fax Referral To: 1-855-297-1270 Address: 6020 Ave Roberto Sanchez Vilella, PR 00982

Phone: 1-888-280-1190 NCPDP: 4026325

	Six Simple S	teps to Submitting a R	eferral		
PATIENT INFORMAT	FION (Complete or include	demographic sheet)			
Patient Name:	·	DOB:		Gender: 🗌 Male 🔲 Female	
Address:		City, State, ZIP	Code:		
Note: Carrier charges may apply. B	y providing the phone number(s) and ema	il address above, you are consenting	g to receive automated	Email (to email provided below d calls, emails and/or text messages from C ntact via text or email, Specialty Pharmacy	
		Alternate Phone:			
Email:		Last Four of SSN:	Primary Langu	uage:	
Parent/Caregiver/Legal Gu	ardian Name (Last, First):	Relationship t	o patient:		
2 PRESCRIBER INFOR	MATION				
Facility Type: 🔲 Private Pr	actice 🗌 Outpatient Hospital/Cl				
Prescriber's First Name:	Pı	rescriber's Last Name:			
NPI#:	State License#:	DEA#:			
			Fax Number:		
Office Contact Name:		Contact's Phone:			
Ls the Patient Insured? ☐ \ Policy Holder's Name: Medical Insurance:	MATION Please fax copy of pr Yes □ No Is the Patient enrolle Teleph Group #:	ed or eligible for Medicare/M Policy Holder's DOB: lone: Policy ID:	ledicaid?	☐ No ship to Patient: Group #:	
Chook box if patient is or	nrolled in manufacturer copay as	cictopoo If you places prov	K.	X PCN #	
Diagnosis (ICD-10):  ☐ F53.0 Postpartum Depre  Patient Clinical Information  Allergies:	<del></del>				
If YES, list all previous medi	n treated for Postpartum Depress cations				

## Zurzuvae Enrollment Form Please Complete Patient and Prescriber Information

Patient Phone:

Patient DOB:

Patient Name:

Patient Address:					
Prescriber Name:	Prescriber Phone:				
5 PRESCRIPTION INFORMATION (to be completed by prescri	riber only)				
Treatment information for Prescribers					
<ul> <li>Recommended dosage is 50mg orally once daily in the evening for 14 days</li> </ul>					
<ul> <li>Severe Hepatic Impairment: Recommended dosage is 30mg orally once daily in evening for 14 days</li> </ul>					
Moderate or Severe Renal Impairment: Recommended dosage is 30mg orally once daily in the evening for 14 days					
For additional information, please refer to full prescribing informati	on: Zurzuvae Prescribing Information				
<b>NOTE</b> : Prescriber must comply with his/her state-specific prescription requirements substitution or any other prescription element which may be required and that is not capermitted by the applicable law in your state. The prescriber should include all required.	aptured by this form. For this reason, the prescription form below should only be used if				
Patient Name (First and Last):	Patient Date of Birth:				
Patient Address:					
Drug Name, Strength, and Dosage Form:					
Directions/Sig:					
Quantity Authorized (Numeric): (Written):	Refills:				
Prescriber Name: Prescriber Phone Number:					
Prescriber DEA #:	State License #:				
Prescriber Address:					
Supervising Physician Name:	Supervising Physician Phone Number:				
Supervising Physician Address:					
6 PRESCRIBER SIGNATURE REQUI	RED (STAMP SIGNATURE NOT ALLOWED)				
May Substitute/ Product Selection Permitted / Substitution Permissible	Dispense As Written/ Brand Medically Necessary / Do Not Substitu / No Substitution / DAW / May Not Substitute				
Prescriber's Signature: Date:	Prescriber's Signature: Date:				
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the	words "No Substitution"				
ATTN: New York and Iowa providers, please submit electronic prescription					

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

I have obtained written authorization from the Patient to disclose the Patient's personal health information and any other information on this enrollment form as may be required to comply with all applicable federal and state laws and regulations, including, but not limited to, the HIPAA Privacy Rule (45 C.F.R. Parts 160 and 164) and the Confidentiality of Substance Use Disorder Patient Records Regulation (42 C.F.R. Part 2), as amended from time to time.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.